Alberta Childhood COVID-19 Cohort (AB3C) Aim 3: Longitudinal Sero-Epidemiology Study First Interim Report January 31, 2021

Simple item page
dc.contributor.authorKellner, James
dc.date.accessioned2021-02-09T23:17:47Z
dc.date.available2021-02-09T23:17:47Z
dc.date.issued2021-01-31
dc.descriptionFunded by Government of Alberta and Alberta Children's Hospital Research Instituteen_US
dc.description.abstractThe AB3C study has three primary aims: 1. Establish prospective cohort study of all children in Alberta tested for or diagnosed with confirmed or probable COVID-19 infection. (Funded by Alberta Children’s Hospital Research Institute (ACHRI)) 2. Conduct a detailed multiomic precision-medicine evaluation of some children in Alberta with confirmed or probable COVID-19 infection, as well as some healthy controls. (Funded by Genome Alberta) 3. Evaluation of the adaptive immune response to SARS-CoV-2 virus in children will be conducted measuring the antibody response against COVID-19 in children with and without clinically apparent confirmed or probable COVID-19 infection in a longitudinal sero-epidemiology study over two years. (Funded by Alberta Health and ACHRI) The AB3C study has received research ethics and operational approval from the University of Calgary’s and Alberta Health Services’ Conjoint Health Research Ethics Board (CHREB). This report describes the results of the enrolment and first of four visits for Aim 3.en_US
dc.description.grantingagencyOtheren_US
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/38639
dc.identifier.urihttp://hdl.handle.net/1880/113084
dc.language.isoengen_US
dc.publisher.departmentPaediatricsen_US
dc.publisher.facultyCumming School of Medicineen_US
dc.publisher.institutionUniversity of Calgaryen_US
dc.relation.ispartofseriesSeries 1 / Report No. 1en_US
dc.subjectSARS-CoV-2en_US
dc.subjectCOVID-19en_US
dc.subjectimmunityen_US
dc.subjectserologyen_US
dc.subjectchildrenen_US
dc.subjectpandemicen_US
dc.subjectvaccineen_US
dc.titleAlberta Childhood COVID-19 Cohort (AB3C) Aim 3: Longitudinal Sero-Epidemiology Study First Interim Report January 31, 2021en_US
dc.typedataseten_US
dc.typereporten_US
dc.typeworking paperen_US
ucalgary.item.requestcopytrueen_US
ucalgary.scholar.levelFacultyen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
AB3C Aim 3 1st Interim Report-final.pdf
Size:
745.22 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.92 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Cumming School of Medicine Research & Publications